SCHEMBL3986060

SCHEMBL3986060

COc1cccc(Cn2nc(C)c3c(c(O)c4n3CCN(C)C4=O)c2=O)c1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PDE5A O76074 1/20 0.45
PKM P14618 4/20 0.45
ALDH1A1 P00352 4/20 0.45
GAA P10253 3/20 0.45
MAPT P10636 1/20 0.42
CMA1 P23946 1/20 0.41
TP53 P04637 2/20 0.40
AURKA O14965 1/20 0.40
AURKB Q96GD4 1/20 0.40
RXFP1 Q9HBX9 2/20 0.39
USP2 O75604 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C19 P33261 1/20 0.39
ADORA3 P0DMS8 1/20 0.39
SIGMAR1 Q99720 1/20 0.38
KDM4E B2RXH2 1/20 0.38
PIK3R1 P27986 1/20 0.38
PIK3CA P42336 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3992564 0.90 PDE5A (0.38) PDE5AALDH1A1MAPTTP53RXFP1
SCHEMBL3985745 0.89 NPBWR1 (0.37) PKMALDH1A1MAPTCMA1AURKA
SCHEMBL3983972 0.88 RXFP1 (0.40) PKMALDH1A1MAPTRXFP1KDM4E
SCHEMBL3989304 0.88 LMNA (0.41) PKMALDH1A1MAPTTP53ADORA3
SCHEMBL3985461 0.87 PDE5A (0.39) PDE5AGAAMAPT
SCHEMBL3994378 0.85 ABHD6 (0.43) ALDH1A1GAAMAPTKDM4E
SCHEMBL3985002 0.85 NPBWR1 (0.35) PDE5APKMTP53
SCHEMBL3985863 0.83 PKM (0.35) PKMALDH1A1GAAMAPTTP53
SCHEMBL3981492 0.83 MAOB (0.40) ALDH1A1GAAMAPTTP53CYP3A4
SCHEMBL3985346 0.83 PKM (0.36) PKMALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7538112-B2 HIV integrase inhibitors MERCK & CO., INC. (US) 2009-05-26 US claimed
US-20080287394-A1 Hiv Integrase Inhibitors MERCK & CO., INC. (US) 2008-11-20 US claimed
EP-1756114-B1 HIV INTEGRASE INHIBITORS MERCK SHARP & DOHME (US) 2014-11-19 EP disclosed
US-7538112-B2 HIV integrase inhibitors MERCK & CO., INC. (US) 2009-05-26 US disclosed
US-7538112-B2 HIV integrase inhibitors MERCK & CO., INC. (US) 2009-05-26 US disclosed
US-20080287394-A1 Hiv Integrase Inhibitors MERCK & CO., INC. (US) 2008-11-20 US disclosed
US-20080287394-A1 Hiv Integrase Inhibitors MERCK & CO., INC. (US) 2008-11-20 US disclosed
US-20080287394-A1 Hiv Integrase Inhibitors MERCK & CO., INC. (US) 2008-11-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287394-A1 Hiv Integrase Inhibitors DHPS, DPYD, TYMP PDE5A 422/4885PKM 1268/4885ALDH1A1 913/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.